ArticleEClinicalMedicine2025
Arterial and venous thromboembolic events in patients with cancer treated with targeted therapies: a population-based cohort study.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Risks of Retinal Vascular Occlusions with the Systemic Use of Tyrosine Kinase Inhibitors.Ophthalmology. Retina · 2026Article
- Venous thromboembolism risk in sarcoma patients receiving combined immune checkpoint inhibitors and VEGF pathway inhibitors: a real-world cohort study.Translational cancer research · 2026Article
- Cancer-Associated Thrombosis in Patients Treated with Immune Checkpoint Inhibitors.International journal of molecular sciences · 2026Review
- Weighing the evidence on cabozantinib and thrombotic risk.Blood advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging data suggest a substantial risk of arterial and venous thromboembolic events (ATE/VTE) associated with targeted cancer therapies. We examined the association between selected targeted therapies and ATE/VTE-risk using Danish population-based healthcare data. Methods: We identified 41,744 patients with cancer treated with selected targeted therapies between January 2004 and December 2020. We computed cumulative incidence functions and 95% confidence intervals (CIs) of ATE/VTE after therapy initiation, considering death as competing event. A multivariable Cox proportional hazards regression analysis with time-varying exposure to targeted therapy was conducted for selected cancers, calculating hazard ratios (HRs) and 95% CIs for ATE/VTE, enabling the comparison of the time periods with and without targeted therapy, adjusting for age, sex, comorbidity burden, cancer stage, and year of diagnosis. Findings: The three-year cumulative ATE-incidence was 3.7% (95% CI: 3.2-4.2) with immune checkpoint inhibitors (ICI; n = 7880), 3.4% (95% CI: 2.8-4.1) with multi-kinase inhibitors (MKI; n = 3394), 2.6% (95% CI: 1.9-3.5) with cyclin dependent kinase (CDK) 4/6-inhibitors (n = 1966), 2.5% (95% CI: 1.0-5.4) with anaplastic lymphoma kinase (ALK)-/ROS1-targeted therapies (n = 199), 2.6% (95% CI: 2.2-2.9) with epidermal growth factor receptor (EGFR)-targeted therapies (n = 8603), 2.4% (95% CI: 2.1-2.7) with vascular endothelial growth factor (VEGF)-targeted therapies (n = 12,802), and 1.4% (95% CI: 1.2-1.6) with human epidermal growth factor receptor 2 (HER2)-targeted therapies (n = 11,683). The three-year VTE-incidence was highest for EGFR- (9.3% [95% CI: 8.7-9.9]), ALK/ROS- (9.2% [95% CI: 5.7-13.8]), VEGF-targeted therapies (8.8% [95% CI: 8.3-9.3]), and ICI (8.1% [95% CI: 7.5-8.8]), followed by 7.5% (95% CI: 6.7-8.5) with MKI, 6.9% (95% CI: 5.7-8.3) with CDK4/6-inhibitors, and 3.4% (95% CI: 3.1-3.8) with HER2-targeted therapies. Among patients with selected cancer types, time-dependent exposure to certain targeted therapies was associated with an increased risk of ATE and/or VTE. Interpretation: Selected targeted therapies pose a clinically meaningful risk of ATE and VTE in patients with cancer. Funding: Department of Clinical Epidemiology, Center for Population Medicine, Aarhus University and Aarhus University Hospital, Denmark and the Independent Research Fund Denmark (3101-00102B).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.